The NHance<sup>®</sup> Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients

The NHance<sup>®</sup> Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients

Dysregulation of MET signaling has been implicated in tumorigenesis and metastasis. ARGX-111 combines complete blockade of this pathway with enhanced tumor cell killing and was investigated in 24 patients with MET-positive advanced cancers in a phase 1b study at four dose levels (0.3–10 mg/kg). ARGX...

Full description

Bibliographic Details
Main Authors: Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Philippe Barthélémy, Christophe Borg, Keunchil Park, Do-Youn Oh, Sang-We Kim, Natalie De Jonge, Valérie Hanssens, Karen Zwanenpoel, Carla Molthoff, Daniëlle Vugts, Torsten Dreier, Peter Verheesen, Guus A.M.S. van Dongen, Julie Jacobs, Luc Van Rompaey, Anna Hultberg, Paolo Michieli, Patrick Pauwels, Samson Fung, Alain Thibault, Hans de Haard, Nicolas Leupin, Ahmad Awada
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Biomedicines
Subjects:
MET
18F-FDG-PET/CT
antibody
cancer
Online Access:https://www.mdpi.com/2227-9059/9/6/665

Internet

https://www.mdpi.com/2227-9059/9/6/665

Similar Items